MANE — Veradermics, Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1827635 ·
Last close
$116.57
Market Cap
$4.87B
52W High
$131.24
52W Low
$32.00
ADV30
695,760
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -29,553,000 | -23,502,000 | 825,735,000 | 319,333,000 | 12,122,000 |
| Mar 2026 | 0 | — | -29,713,000 | -27,232,000 | 397,356,000 | 168,412,000 | 6,716,000 |
| Dec 2025 | 0 | — | -22,753,000 | -21,847,000 | 152,619,000 | 21,766,000 | 273,633,000 |
| Sep 2025 | — | — | — | — | 18,797,000 | 5,660,000 | 114,812,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-61,745,000
Investing CF
$-226,827,000
Financing CF
$477,354,000
CapEx
$-24,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.68
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-150,653,000
Inventory
—
Receivables
$1,651,000
ST Investments
$222,385,000
EBIT TTM
$-69,810,000
Pretax Income TTM
$-67,139,000
Interest Exp TTM
$292,000
Analysts
6
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -71,557,000 | -69,995,000 | 152,619,000 | 273,633,000 | -121,014,000 | -71,602,000 |
| Dec 2024 | 0 | -26,384,000 | -26,488,000 | 55,535,000 | 104,015,000 | -48,480,000 | -23,688,000 |
| Dec 2023 | 0 | -17,324,000 | -16,490,000 | 17,562,000 | 39,804,000 | -22,242,000 | -13,510,000 |
TTM Snapshot
Revenues TTM
$482,000
NetIncome TTM
$-12,400,000
OpCashFlow TTM
$0
Assets (Latest)
$152,619,000
Forward EPS
$-2.69
Max Pain — expiry 2026-10-16
max pain strike: $105.00 · spot: $115.19 · call oi: 497 · put oi: 2,340
Expected Move to 2026-10-16:
±$22.80
(19.79%) —
implied range
$92.39 –
$137.99
· ATM straddle on $115.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.95B | $88.55 | — |
| ERAS | Erasca, Inc. | $4.98B | $14.25 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.23B | $62.67 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.27B | $39.34 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.59B | $84.46 | — |
News headlines (Yahoo Finance, 1h cache)
Veradermics to Present at Upcoming September Investor Conferences
2026-09-03 21:33 · Yahoo
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
2026-09-03 01:06 · Yahoo
Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?
2026-09-02 22:15 · Yahoo
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
2026-08-31 03:21 · Yahoo
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026
2026-05-21 03:02 · Yahoo
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
2026-09-12 00:29 · Yahoo
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-08-11 11:30 · Yahoo
Veradermics (MANE) Positioned to Disrupt Hair Loss Market
2026-08-04 15:08 · Yahoo
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
2026-07-19 19:31 · Yahoo
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
2026-07-17 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.